05.05.2022 APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights | APONTIS PHARMA AG | News | Nachricht | Mitteilung
Investegate announcements from APONTIS PHARMA AG, APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with pan-European intellectual property rights
Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,